Cited by 390Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers

Open access

Sharma, Anu, Subudhi, Sumit K., Blando, Jorge, Scutti, Jorge, Vence, Luis, Wargo, Jennifer, Allison, James P., Ribas, Antoni, Sharma, Padmanee·2019·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-18-0762PMC PMC6348141

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Purpose: CTLA-4 was the first inhibitory immune checkpoint to be identified. Two mAbs, ipilimumab (IgG1) and tremelimumab (IgG2), which block the function of CTLA-4, have demonstrated durable clinical activity in a subset of patients with advanced solid malignancies by augmenting effector T-cell–mediated immune responses. Studies in mice suggest that anti-CTLA-4 mAbs may also selectively deplete intratumoral FOXP3+ regulatory T cells via an Fc-dependent mechanism. However, it is unclear whether the depletion of FOXP3+ cells occurs in patients with cancer treated with anti-CTLA-4 therapies. Experimental Design: Quantitative IHC was used to evaluate the densities of intratumoral CD4+, CD8+, and FOXP3+ cells in stage-matched melanoma (n = 19), prostate cancer (n = 17), and bladder cancer (n = 9) samples treated with ipilimumab and in paired melanoma tumors (n = 18) treated with tremelimumab. These findings were corroborated with multiparametric mass cytometry analysis of tumor-infiltrating cells from paired fresh melanoma tumors (n = 5) treated with ipilimumab. Results: Both ipilimumab and tremelimumab increase infiltration of intratumoral CD4+ and CD8+ cells without significantly changing or depleting FOXP3+ cells within the tumor microenvironment. Conclusions: Anti-CTLA-4 immunotherapy does not deplete FOXP3+ cells in human tumors, which suggests that their efficacy could be enhanced by modifying the Fc portions of the mAbs to enhance Fc-mediated depletion of intratumoral regulatory T cells. See related commentary by Quezada and Peggs, p. 1130

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-18-0762

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Self-citation
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Self-citation
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · cited 1×
“CTL-associated protein 4 (CTLA-4) is an inhibitory immune checkpoint receptor that plays a crucial role in modulating T-cell responses (1, 2).”
BackgroundSelf-citation
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,996
viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia
Amir, E.-A. D., Davis, K. L., Tadmor, M. D., Simonds, E. F., Levine, J. H., Bendall, S. C., Shenfeld, D. K., Krishnaswamy, S., Nolan, G. P., & Pe'er, D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2594 · Cited by 1,550

Show all 33 references

Sorted by citations

Items 301–390 of 390

TERT promoter methylation predicts overall survival, immune cell infiltration and response to immunotherapy in clear cell renal cell carcinoma
Guan, X., Meng, J., Yi, W., Ye, K., Gao, H., Hong, Y., Qu, L., Ding, S., & Qian, L. (2025) · Clinical Epigenetics · doi:10.1186/s13148-025-01897-x · Cited by 3
Facts and Hopes in Harnessing Macrophage-Mediated Antibody-Dependent Cellular Phagocytosis for Cancer Immunotherapy
Armero, M., Smolkin, M., García‐Domínguez, M., Berraondo, P., Melero, I., & Gálvez‐Cancino, F. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0434 · Cited by 3
Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer
Mahadevan, K. K., Maldonado, A. S., Li, B., Bickert, A. A., Perdyan, A., Kumbhar, S. V., Piya, S., Sockwell, A. M., Morse, S. J., Arian, K. A., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-75960-3 · Cited by 12
CRISPR/Cas9-based Engineering of Immunoglobulin Loci in Hybridoma Cells
Gall, C. M. L., Fennemann, F. L., van der Schoot, J. M. S., Scheeren, F. A., & Verdoes, M. (2023) · BIO-PROTOCOL · doi:10.21769/bioprotoc.4613 · Cited by 3
The Great Debate at ‘Immunotherapy Bridge’, Naples, December 5, 2019
Ascierto, P. A., Bifulco, C. B., Galon, J., Garbe, C., Khleif, S. N., McQuade, J. L., Odunsi, K. O., Okada, H., Paulos, C. M., Quezada, S. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000921 · Cited by 4
Optimal strategy in managing advanced melanoma
Uchi, H. (2023) · The Journal of Dermatology · doi:10.1111/1346-8138.17068 · Cited by 3
Microfluidics for Immuno‐oncology
Ma, C., Harris, J., Morales, R. T., & Chen, W. (2019) · Wiley eBooks · doi:10.1002/9783527818341.ch5 · Cited by 3
FcyRIIB Is a Novel Immune Checkpoint in the Tumor Microenvironment Limiting Activity of Treg-Targeting AntibodiesPreprint
Knorr, D. A., Leidner, R. S., Jensen, S. M., Meng, R., Jones, A., Ballesteros‐Merino, C., Bell, R. B., Baez, M., Sprott, D., Bifulco, C. B., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.19.522856 · Cited by 3
Intratumoral Treg ablation is sufficient to mediate tumor control systemically without autoimmunityPreprint
Bockman, A., Gittins, B. J., Zhang, C., Hung, J. S.-C., Ayala, M. M., Axe, D. S., Weist, B. M., & DuPage, M. J. P. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.26.661765 · Cited by 3
Targeting Tregs in pancreatic ductal adenocarcinoma
Siegel, M., Prabhu, A., Hussain, S., Nwachukwu, D., & Ali, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23523-8.00015-8 · Cited by 2
Circulating Plasma Proteins as Biomarkers for Immunotherapy Toxicity: Insights from Proteome-Wide Mendelian Randomization and Bioinformatics Analysis
Tang, L., He, W., Hu, H., Liu, J., & Li, Z. (2025) · Biomedicines · doi:10.3390/biomedicines13071717 · Cited by 2
Longitudinal tissue analysis reveals microenvironmental changes correlate with combined immunotherapy and targeted therapy response in metastatic breast cancer
Liao, J., Wang, J., Li, H., Liu, Z., Tian, Z., Lv, X., Peng, J., Song, C., & Liu, J. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012629 · Cited by 3
Targeting LRBA triggers CTLA4 degradation and antitumor immunity for cancer immunotherapy
Ge, X., Yu, L., Zhang, L., Jia, L., Meng, M., He, J., Bu, F., Song, Y., Sun, G., Lv, S.-M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67365-5 · Cited by 3
Immune checkpoint inhibitors in bladder cancer: from mechanistic insights to emerging combination frontlines
Ajalli, M. M., Sansebli, Y., Ekrami, D., Alaeenejad, F., Abbasi, A., Eini, P., Hassanzadeh, F., & Bahrami, N. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02098-3 · Cited by 2
Capturing and Tracking Clonal T-cell Response to Cancer Neoantigens
Shagina, I. A., Nakonechnaya, T. O., Izosimova, A. V., Shabalkina, A. V., Yuzhakova, D. V., Skatova, V. D., Lupyr, K. R., Muftakhutdinov, I., Izraelson, M., Davydov, A. N., et al. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-1216 · Cited by 4
Rethinking biomarker strategy in gastric cancer immunotherapy: from tumor to host
Ismaili, N. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1847526 · Cited by 2
An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition
Naidoo, J., Dykema, A. G., & D’Alessio, F. R. (2018) · Journal of Clinical Investigation · doi:10.1172/jci125800 · Cited by 2
Modern aspects of immunotherapy with checkpoint inhibitors in melanoma
Vladimirova, L. Y., Teplyakova, M. A., Попова, И. Л., Абрамова, Н. А., Tikhanovskaya, N. M., Льянова, А. А., Эдуардовна, С. А., Алексеевна, Р. Л., Kabanov, S. N., Kalabanova, E. A., et al. (2022) · Medical alphabet · doi:10.33667/2078-5631-2022-26-35-40 · Cited by 2
TO MARKET, TO MARKET–2022: MACROMOLECULAR THERAPEUTICS
Lim, S. A., Agard, N. J., Kelly, R. L., Bell, B. N., Chen, S.-J., Gram, A. M., Merritt, J. R., Moench, I., Pance, K., & Petojevic, T. (2023) · Medicinal chemistry reviews · doi:10.1021/mc-2023-vol58.ch25 · Cited by 2
Soluble CTLA-4 raises the threshold for T-cell activation and modulates anti-tumour immunityPreprint
Kennedy, P. T., Saulters, E. L., Duckworth, A. D., Lim, Y. J., Woolley, J. F., Slupsky, J. R., Cragg, M. S., Ward, F. J., & Dahal, L. N. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.05.543731 · Cited by 2
Potentiating Salvage Radiotherapy in Radiorecurrent Prostate Cancer Through Anti-CTLA4 Therapy: Implications from a Syngeneic Model
Wang, H., Gong, L., Huang, X., White, S. D., Chung, H. T.-K., Vesprini, D., Petchiny, T. N., Fokas, E., He, H. H., Kerbel, R. S., et al. (2024) · Cancers · doi:10.3390/cancers16162839 · Cited by 1
Targeting intratumoral Tregs: The promise of CD25×TIGIT bispecific antibodies in solid tumor therapy
Venkatachalapathy, M. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.10.013 · Cited by 2
Association between antibody-dependent cellular cytotoxicity activity of antitumor antibodies and infusion reactions: a pharmacovigilance analysis using the Japanese adverse drug event report database
Tabuchi, Y., Tsujimoto, M., Kise, Y., Sakamoto, T., Matsuda, M., Kosaka, T., & Nishiguchi, K. (2025) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-025-00481-y · Cited by 1
Unlocking the Immune System: Advances in Next-generation Immunotherapy for Lung Cancer
Choudhary, F., Safdar, A., Abdin, M. Z., & Farooqi, H. (2025) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575415429251007093531 · Cited by 1
Fluorescence tracking Treg movement identifies anti-CCR8 and radiation as a therapeutic combination
Friedman, D. J., Ramin, S., Blair, T. C., Kramer, G. F., Bambina, S., Alice, A. F., Baird, J., Medler, T. R., Young, K. H., Crittenden, M. R., et al. (2025) · iScience · doi:10.1016/j.isci.2025.114572 · Cited by 1
Advances in Cancer Immunotherapy Regulators of Immune Checkpoints and Effects on the Heart
Iqbal, M., & Jiménez, J. (2026) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-025-01134-x · Cited by 1
Spatially-resolved single-cell imaging of melanoma brain metastases identifies localized immune patterns predictive of immune checkpoint blockade response
Voglis, S., Schulz, D., Eling, N., de Souza, N., Regli, L., Neidert, M. C., Czabanka, M., Weller, M., Rhun, É. L., Mihic‐Probst, D., et al. (2026) · Neuro-Oncology · doi:10.1093/neuonc/noag128 · Cited by 1
CD3high and FoxP3− tumor-infiltrating lymphocytes in the invasive margin as a favorable prognostic marker in patients with invasive urothelial carcinoma of the bladder
Sun, Z.-J., Zhao, J., Zhao, M., Chen, Y., Zhang, X., Li, H., Wu, G., & Zhang, D. (2022) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001468 · Cited by 1
A novel antibody targeting ICOS increases intratumoural cytotoxic to regulatory T cell ratio and induces tumour regressionPreprint
Sainson, R. C. A., Thotakura, A. K., Kosmač, M., Borhis, G., Parveen, N., Kimber, R., Carvalho, J., Henderson, S. C., Pryke, K. L., Okell, T., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/771493 · Cited by 1
Tracking antigen-specific T cell response to cancer immunotherapyPreprint
Shagina, I. A., Nakonechanaya, T. O., Izosimova, A. V., Yuzhakova, D. V., Skatova, V. D., Lupyr, K. R., Izraelson, M., Davydov, A. N., Shugay, M., Britanova, O. V., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.29.626027 · Cited by 1
Quelles chaînes lourdes d’immunoglobulines pour quels anticorps d’immunostimulation ?
Dumet, C., & Watier, H. (2019) · médecine/sciences · doi:10.1051/medsci/2019241
Le rôle des lymphocytes T régulateurs dans l’activité antitumorale des anticorps anti-CTLA-4
Thierry, K., & Ménétrier‐Caux, C. (2020) · médecine/sciences · doi:10.1051/medsci/2019260
The Biomarkers of Cd4+ T Regulatory Cells Associated with Tumour Immune Escape
Nyaribari, M. (2020) · International Journal of Immunotherapy and Cancer Research · doi:10.17352/2455-8591.000028
Anti-tumor effect of CTLA-4 antibody is independent of checkpoint blockadePreprint
Gao, H. J., Cai, H., Zhang, F., Liu, M., Wang, X., Wang, P., Dou, F., Li, F., Xu, T., & Zhou, A. (2021) · Research Square · doi:10.21203/rs.3.rs-907762/v1
Acidosis Significantly Alters Immune Checkpoint Expression Profiles of T CellsPreprint
Davern, M., Donlon, N. E., Connell, F. O., Gaughan, C., Donovan, C. O., Habash, M. M., Sheppard, A. D., MacLean, M., Dunne, M. R., Moore, J., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3946994
Predictive value of inflammatory indices LMR, PLR and NLR in patients with muscle-invasive bladder cancer
Ai, G., Zhuravskii, D. A., & Gorelova, A. A. (2021) · Urology reports (St - Petersburg) · doi:10.17816/uroved83815
Faculty Opinions recommendation of Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.
Sanz‐Moreno, V. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735007057.793567353
Regulatory T Cells as Potential Therapeutic Targets for Anticancer Therapy
殷, 方. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.12101340
Regulatory Cell Subset Responses in Cancerous Diseases: Pathophysiological and Clinical Challenges
Tsiogkas, S. G., Dardiotis, E., Rigopoulou, E. I., & Bogdanos, D. P. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_7-1
Mechanisms of Immunological Toxicity in Cancer Immunotherapy with Checkpoint Inhibitors
Polaczek, M. M., & Piotr, R. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_360-1
Depletion of effector regulatory T cells drives major response to induction dual immune checkpoint blockadePreprint
Jiang, X., Rudqvist, N.-P., Jiang, B., Ye, S., He, S., Liang, Q., Dou, J., Williams, M. D., Dunn, J. D., Johnson, J. M., et al. (2024) · medRxiv · doi:10.1101/2024.01.04.23300616
Lipid-based nanomedicines for cancer immunotherapy
Wahab, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18770-4.00009-3
The Nephrotoxicity of Checkpoint Inhibitors: A Mini Review
Mahmoodpoor, F., Ardalan, M., Nasibova, A. N., Valiyeva, M. N., & Ahmadian, E. (2024) · International Journal of Drug Research in Clinics · doi:10.34172/ijdrc.2024.e1
Immunobiology of Cancer
Verma, N., Thapa, K., Kanojia, N., & Chandel, P. (2024) · Springer eBooks · doi:10.1007/978-981-97-3001-8_2 · Cited by 1
Research Progress of Molecular Imaging in Immunotherapy for Colorectal Cancer
易, 泽. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.14112946
Application of Immunotherapy in the Gynecological Tumors
Shi, H. (2024) · Highlights in Science Engineering and Technology · doi:10.54097/gqtct139
Analysis of CD8 and FOXP3 Expression Ratios in Tumor and Stromal Compartments of Penile Squamous Cell Carcinoma Across Different Subtypes and GradesPreprint
Cañete‐Portillo, S., Cubilla, A. L., Netto, G. J., & Chaux, A. (2025) · medRxiv · doi:10.1101/2025.01.11.25320379
Regulatory T Cells in Tumor Immunity
Kang, J. H., Nagarsheth, N., Kryczek, I., Wei, S., Frankel, T. L., Zou, W., & Zappasodi, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00201-5
CD4+ T cells in Antitumour Immunity
Bawden, E., & Gebhardt, T. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00187-3
A novel anti-human CD25 mAb with preferential reactivity to activated T regulatory cells depletes them from the tumor microenvironment
Buszko, M., Jones, M., Chempati, S., Morina, L., Ward, K., Habte, H. H., Dziegielewski, M., & Shevach, E. M. (2025) · Oncotarget · doi:10.18632/oncotarget.28752
Regulatory Cell Subset Responses in Cancerous Diseases: Pathophysiological and Clinical Challenges
Tsiogkas, S. G., Dardiotis, E., Rigopoulou, E. I., & Bogdanos, D. P. (2025) · Springer eBooks · doi:10.1007/978-3-032-00749-0_7
Integrating Mathematical and Mouse Models Identifies T Regulatory Cell Influx as A Key Determinant of Acquired Resistance to PD-1 ImmunotherapyPreprint
Sousa, R. S., Geels, S. N., Murat, C., Moshensky, A., Villalta, S. A., Lowengrub, J. S., & Marangoni, F. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.31.685923
Additional file 7 of Interaction of immune cells with renal cancer development: Mendelian randomization (MR) study
Lu, Z., Yin, Y., Rao, T., Xu, X., Zhao, K., Liu, Z., Qin, C., & Tang, M. (2024) · Figshare · doi:10.6084/m9.figshare.26704458
Additional file 6 of Loss of endothelial EMCN drives tumor lung metastasis through the premetastatic niche
Zhang, G., Li, M., Zhou, D., Yang, X., Zhang, W., & Gao, R. (2022) · Figshare · doi:10.6084/m9.figshare.21261649
Additional file 5 of Interaction of immune cells with renal cancer development: Mendelian randomization (MR) study
Lu, Z., Yin, Y., Rao, T., Xu, X., Zhao, K., Liu, Z., Qin, C., & Tang, M. (2024) · Figshare · doi:10.6084/m9.figshare.26704452
Additional file 1 of Interaction of immune cells with renal cancer development: Mendelian randomization (MR) study
Lu, Z., Yin, Y., Rao, T., Xu, X., Zhao, K., Liu, Z., Qin, C., & Tang, M. (2024) · Figshare · doi:10.6084/m9.figshare.25572623
Additional file 4 of Loss of endothelial EMCN drives tumor lung metastasis through the premetastatic niche
Zhang, G., Li, M., Zhou, D., Yang, X., Zhang, W., & Gao, R. (2022) · Figshare · doi:10.6084/m9.figshare.21261643
Additional file 3 of Loss of endothelial EMCN drives tumor lung metastasis through the premetastatic niche
Zhang, G., Li, M., Zhou, D., Yang, X., Zhang, W., & Gao, R. (2022) · Figshare · doi:10.6084/m9.figshare.21261640
Additional file 9 of Interaction of immune cells with renal cancer development: Mendelian randomization (MR) study
Lu, Z., Yin, Y., Rao, T., Xu, X., Zhao, K., Liu, Z., Qin, C., & Tang, M. (2024) · Figshare · doi:10.6084/m9.figshare.26704464
Additional file 1 of Evaluating the immunologically “cold” tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4 + and CD8 + T cells in breast cancer mouse models
Lü, Y., Houson, H. A., Gallegos, C., Mascioni, A., Jia, F., Aivazian, A., Song, P. N., Lynch, S. E., Napier, T. S., Mansur, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26103786
Additional file 1 of Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination
Ellingsen, E. B., Bounova, G., Kerzeli, I. K., Anzar, I., Simnica, D., Aamdal, E., Guren, T. K., Clancy, T., Mezheyeuski, A., Inderberg, E. M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21080550
Additional file 2 of Loss of endothelial EMCN drives tumor lung metastasis through the premetastatic niche
Zhang, G., Li, M., Zhou, D., Yang, X., Zhang, W., & Gao, R. (2022) · Figshare · doi:10.6084/m9.figshare.21261637
Additional file 1 of Loss of endothelial EMCN drives tumor lung metastasis through the premetastatic niche
Zhang, G., Li, M., Zhou, D., Yang, X., Zhang, W., & Gao, R. (2022) · Figshare · doi:10.6084/m9.figshare.21261634
Additional file 6 of Interaction of immune cells with renal cancer development: Mendelian randomization (MR) study
Lu, Z., Yin, Y., Rao, T., Xu, X., Zhao, K., Liu, Z., Qin, C., & Tang, M. (2024) · Figshare · doi:10.6084/m9.figshare.26704455
Additional file 5 of Loss of endothelial EMCN drives tumor lung metastasis through the premetastatic niche
Zhang, G., Li, M., Zhou, D., Yang, X., Zhang, W., & Gao, R. (2022) · Figshare · doi:10.6084/m9.figshare.21261646
Additional file 7 of Loss of endothelial EMCN drives tumor lung metastasis through the premetastatic niche
Zhang, G., Li, M., Zhou, D., Yang, X., Zhang, W., & Gao, R. (2022) · Figshare · doi:10.6084/m9.figshare.21261652
Additional file 2 of Interaction of immune cells with renal cancer development: Mendelian randomization (MR) study
Lu, Z., Yin, Y., Rao, T., Xu, X., Zhao, K., Liu, Z., Qin, C., & Tang, M. (2024) · Figshare · doi:10.6084/m9.figshare.25572698
Additional file 3 of Interaction of immune cells with renal cancer development: Mendelian randomization (MR) study
Lu, Z., Yin, Y., Rao, T., Xu, X., Zhao, K., Liu, Z., Qin, C., & Tang, M. (2024) · Figshare · doi:10.6084/m9.figshare.26704446
Additional file 4 of Interaction of immune cells with renal cancer development: Mendelian randomization (MR) study
Lu, Z., Yin, Y., Rao, T., Xu, X., Zhao, K., Liu, Z., Qin, C., & Tang, M. (2024) · Figshare · doi:10.6084/m9.figshare.26704449
Additional file 8 of Interaction of immune cells with renal cancer development: Mendelian randomization (MR) study
Lu, Z., Yin, Y., Rao, T., Xu, X., Zhao, K., Liu, Z., Qin, C., & Tang, M. (2024) · Figshare · doi:10.6084/m9.figshare.26704461
Additional file 1 of Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumors
Davis-Marcisak, E. F., Fitzgerald, A. A., Kessler, M. D., Danilova, L., Jaffee, E. M., Zaidi, N., Weiner, L. M., & Fertig, E. J. (2021) · Figshare · doi:10.6084/m9.figshare.15145874
Mechanisms of Immunological Toxicity in Cancer Immunotherapy with Checkpoint Inhibitors
Polaczek, M. M., & Piotr, R. (2025) · Springer eBooks · doi:10.1007/978-3-032-00765-0_360
Translating IL-2/anti-IL-2 antibody complexes treatment for human tumor immunotherapy
Caudana, P. (2018) · theses.fr (ABES) · doi:10.70675/8a93b17bz416az4e49z9a3bz92c1c8a4cf8c
Contribution à l'identification de marqueurs de la réponse des carcinomes bronchiques non à petites cellules aux immunothérapies
Guisier, F. (2019) · theses.fr (ABES) · doi:10.70675/9de2ee5az6556z48b7z97b1zc402c970fc69
Rôle des anticorps monoclonaux au cours des myopathies auto-immunes : de l’étude des auto-anticorps spécifiques des myopathies nécrosantes auto-immunes à la description physiopathologique des myosites induites par l’immunothérapie anti-tumorale
Anquetil, C. (2021) · theses.fr (ABES) · doi:10.70675/dce475d2z4b83z4647z85aczea2eb971762b
Dynamique de la réponse immunitaire au cours du traitement par anticorps bloquant PD-1 dans le cancer : mécanismes et recherche de biomarqueurs
Goubet, A. (2021) · theses.fr (ABES) · doi:10.70675/8b8c4cd9z2b3dz4bfbz87e8z0d21af425571
Identification of Biomarkers Associated With the Combination of Immunotherapy and Anti-Angiogenic Drugs in the Treatment of Mesothelioma : Translational Analyses of the PEMBIB Clinical Trial Combining the Anti-PD1 Monoclonal Antibody Embrolizumab and the Anti-Angiogenic Tyrosine Kinase Inhibitor Nintedanib
Danlos, F. (2021) · theses.fr (ABES) · doi:10.70675/ff8cb58bzc391z43f8zbd32zc8c4b2cdc725
Rôle des lymphocytes T Résidents Mémoires (TRM) et des intégrines CD103 et CD49a dans la réponse aux immunothérapies ciblant PD-1 et CTLA-4
Damei, I. (2022) · theses.fr (ABES) · doi:10.70675/415eefc7z95c8z492ez89beze36410b45ef5
Mouse models of immune-related adverse events: progress, challenges, and opportunities
Παπαδόπουλος, Θ., Pinto, A., Abraham, M. J., Naranjo, C. L., Molina, M. F., Hudson, M., Miller, W. H., & Rincon, S. V. D. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.04.010
Intratumoral Regulatory T-cell Ablation Mediates Tumor Control Systemically without Autoimmunity
Bockman, A., Zhang, C., Gittins, B. J., Hung, J., Campbell, T. F., Ayala, M. A. M., Axe, D. S., Weist, B. M., & DuPage, M. J. P. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-3473
Immunotherapy: blockade of CTLA-4/B7 and PD-1/PD-L1 pathways in anticancer therapy. Part 2. Clinical aspects
Shukshin, A. A., Rubinstein, A., Головкин, А. С., Моисеева, О. М., & Kudryavtsev, I. V. (2026) · Medical academic journal · doi:10.17816/maj641690
Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy–Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones
George, M. M., Hamadene, L., Marouf, Y., Ceglia, N., Hirschhorn, D., Schulze, I., Dong, L., Venkatesh, D., Maniyar, R. R., Budhu, S., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-3863
Encapsulated cell therapy for local anti-CTLA-4 delivery in cancer immunotherapy
Engel, A., Vernet, R., Charrier, E., Urwyler, M., Rohr, O. V., Saingier, V., Courtout, F., Abukscem, S., Bouvarel, T., Lathuilière, A., et al. (2026) · iScience · doi:10.1016/j.isci.2026.116938
Targeting Immune Checkpoint Proteins in Cancer Therapy and the Potential of RNAi-Based Immunotherapy
Wang, K. K., & Yu, A. (2026) · Pharmaceuticals · doi:10.3390/ph19081212
Harnessing biomineralization for in situ encapsulating dead tumor cell bodies with enhanced immunogenicity toward tumor-specific personalized immunotherapy
Xu, B., Ji, H., Fan, Y., Liu, J., Zhang, Y., & Wan, Y. (2026) · Chinese Chemical Letters · doi:10.1016/j.cclet.2026.113280
Spatial Treg niches and the therapeutic reprogramming of tumour tolerance in cancer
Bautista, J., Delgado, M. D. C., Viteri-Recalde, J., Benítez-Núñez, M., Ramírez-Sánchez, D., & López-Cortés, A. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1921036
Quantitative Systems Pharmacology Model Predicts Enhanced Antitumor Efficacy of Combined Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) and Programmed Cell Death Protein 1 (PD-1) Blockade in a Syngeneic Mouse Model of Breast Cancer
Zhang, Y., Wang, H., Furukawa, N., Patil, A., Arulraj, T., & Popel, A. S. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00347
Immune-pressure redistribution in resistance to PD-1/PD-L1 blockade: mechanisms, biomarkers, and therapeutic design
Wang, X., Liu, J., Hairulajiang, A., Wang, J., Wang, Q., Li, Z., Zou, B., & Feng, Y. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02786-4
Integrating biology and mathematics to understand checkpoint immunotherapy
Sousa, R. S., Moshensky, A., Murat, C., Geels, S. N., Lowengrub, J. S., & Marangoni, F. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.09.004
The dual role of skin-resident Tregs: balancing autoimmunity in vitiligo and immune evasion in melanoma
Chen, X., Chen, C., & Yang, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1935158

Authors: Sharma, A., Subudhi, S. K., Blando, J., Scutti, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
University of California, Los Angeles (US)
Corresponding author: Sharma, Padmanee
ORCID: Sharma, Anu
Subudhi, Sumit K.
Blando, Jorge
Vence, Luis
Wargo, Jennifer
Allison, James P.
Ribas, Antoni
Sharma, Padmanee
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2019-02-15
Volume: 25
Issue: 4
Pages: 1233-1238
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-18-0762
PMC: PMC6348141
OpenAlex: W4253193856
Cited by: 382
References: 33
Citations by year: 2026: 22 · 2025: 37 · 2024: 62 · 2023: 40 · 2022: 60 · 2021: 60 · 2020: 49 · 2019: 43
FWCI: 15.10
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: HHS | NIH | National Cancer Institute (NCI) (R01 CA1633793)
Prostate Cancer Foundation (PCF) (2014 Stewart Rahr-PCF Young Investigator)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: CTLA-4, anti-CTLA-4 immunotherapy, Foxp3+ regulatory T cells, ipilimumab, tremelimumab, tumor-infiltrating lymphocytes, tumor microenvironment, melanoma, prostate cancer, bladder cancer, mass cytometry, immune checkpoint blockade
MeSH terms: Ipilimumab, Urinary Bladder Neoplasms, Female, Humans, Male, Melanoma, Prostatic Neoplasms, CD4-Positive T-Lymphocytes, Lymphocytes, Tumor-Infiltrating, Paraffin Embedding, CD8-Positive T-Lymphocytes, Cell Lineage, Forkhead Transcription Factors, Tumor Microenvironment, CTLA-4 Antigen, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks